Arkuda Therapeutics, a Watertown MA-based biotechnology company, raised $64M in Series B funding.
The round was led by Cormorant Asset Management and Pivotal bioVenture Partners, with participation from Surveyor Capital, Eli Lilly and Company, Atlas Venture, Pfizer Ventures and Mission BioCapital. Raymond J. Kelleher, M.D., Ph.D., Managing Director at Cormorant Asset Management is a newly appointed member of the Arkuda Board of Directors. Also joining the Arkuda Board is Heather Preston, M.D., Managing Partner at Pivotal bioVenture Partners.
The company intends to use the funds to further exploring the therapeutic potential of its molecules in other neurodegenerative diseases.
Led by Gerhard Koenig, Ph.D., Co-Founder, President and CEO, Arkuda Therapeutics, Arkuda Therapeutics is a biotechnology company applying novel insights at the intersection of lysosomal and microglial biology to develop medicines to change the trajectory of neurodegenerative disease. The company’s lead program aims to correct progranulin deficiency and lysosomal dysfunction in patients with GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the progranulin (GRN) gene.
FinSMEs
15/02/2022